A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy

Summary

Modification of the EGF signalling pathway and / or HER 2, by Lapatinib in bladder cancer.

Timeline

Start

2011-01

Primary completion

2011-10

Completion

2011-10

Outcome

Outcome not reported

Stopped (Enrollment): “The rythm of enrollment was not compatible with the objective of recruitement in the research.”

Publications

• Background Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006 Dec 10;24(35):5536-44. doi: 10.1200/JCO.2006.07.6729.
• Background Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr, Grignon DJ. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001 Aug;7(8):2440-7.
• Background Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6. doi: 10.1016/j.eururo.2005.04.006. Epub 2005 Apr 21.

Drugs

Indications